Remdesivir CAS 1809249-37-3
Port: Shanghai, China
Remdesivir is a nucleoside analog with antiviral activity. In HAE cells, it has an EC50 value of 74 nM for SARS-CoV and MERS-CoV. In delayed brain tumor cells, it has an EC50 value of 30 for murine hepatitis virus. nM
On May 7, 2020, Japan approved Remdesivir developed by Gilead Technology of the United States as the first domestic drug for the treatment of new coronary pneumonia, which will be used for the treatment of critically ill patients. 
On October 22, 2020, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences’ antiviral drug Remdesivir for the treatment of hospitalized patients with new crowns, becoming the first officially approved drug for treatment of new crowns in the United States. 
On November 20, 2020, the World Health Organization issued a statement on the 20th, saying: No matter how severe the condition of the new crown hospitalized patients, it is not recommended to use the antiviral drug remdesivir for treatment, because there is no evidence that the drug can improve the survival rate of patients Or reduce the patient’s demand for ventilators, etc.